Skip to main content

Sigma and Ingex to Develop Prokaryotic Gene-Disruption System

NEW YORK, Oct. 14 (GenomeWeb News) - Germany-based Sigma-Aldrich and St. Louis, Mo.-based Ingex will collaborate in the development of a "novel" targeted prokaryotic gene-disruption technology, Sigma said yesterday in a statement.

 

The companies' TargeTron technology involves targeted insertion of a "TargeTron group II" intron into a host genome, resulting in "permanent" target gene knockout into a variety of prokaryotic genomes, said the statement. Targeted insertion is "more than 90 percent successful" and will work "across a broad range" of prokaryotes, the company added.

 

Future systems are planned for targeted plant and mammalian gene disruption, Sigma said.

 

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.